It is important to highlight, however, the positive effects found for palbociclib or imatinib when used in combinations guided by the present taxonomic findings; since, previous preclinical studies have suggested a limited role for CDK4/6 inhibition in TNBC47, and clinical studies using imatinib alone in unselected48 or c-Kit-positive breast cancer patients has also shown limited efficacy49. Here, KIT is linked to breast carcinoma.